She will continue to push for prescription drug price caps and allow Medicare to negotiate drug prices.
Continue pushing prescription drug price caps and allowing Medicare to negotiate drug prices.
Occurrences
In Congress, Andrea is fighting to increase access to affordable health care for as many folks as possible.
She supports capping the price of insulin and allowing Medicare to negotiate drug prices.
Evidence
Andrea Salinas' campaign issue page said she "supports capping the price of insulin and allowing Medicare to negotiate drug prices to make healthcare more affordable for all families."
The CRS report states that Congress created the Medicare Drug Price Negotiation Program in the Inflation Reduction Act, which became law on August 16, 2022, and that the program allows Medicare to negotiate prices for certain drugs directly with manufacturers for the first time. It also notes CMS selected the first 10 drugs in 2023 and announced negotiated prices in 2024.
Rep. Salinas said Republican legislation blocks low-income seniors from accessing programs that lower their premiums and prescription drug costs, and she used the event to highlight her efforts to protect and strengthen Medicare and seniors' benefits.
The official House homepage listed a June 11, 2026 press release, "Rep. Andrea Salinas Calls on Trump to Uphold His Promise to the American People," saying she delivered House Floor remarks condemning President Trump’s failure to lower costs for the American people.
Assessments
This was a promise to keep advocating for drug-price caps and Medicare drug-price negotiation, not a commitment to pass a new bill by herself. The evidence shows Salinas’ campaign explicitly backed those policies and her House office continued public pressure on lowering prescription and Medicare costs. Medicare drug-price negotiation is already federal law, so the core policy objective is in place, and her ongoing advocacy matches the promise.
The core Medicare drug-price negotiation authority was enacted in the Inflation Reduction Act on August 16, 2022, before Andrea Salinas entered Congress in January 2023, so that portion cannot be credited as a new delivered outcome of her term. The evidence does show she campaigned on insulin caps and Medicare negotiation and continued public advocacy around Medicare and prescription-drug affordability while in office. However, the record provided does not show that she delivered new prescription drug price caps or materially expanded Medicare negotiation during her term. This supports partial fulfillment through continued advocacy, not full delivery.